

REVENIO

Revenio Group Corporation to transfer shares related to the Oculo share-based incentive scheme for 2021-2023

Revenio Group Corporation | Stock Exchange Release | June 12, 2024 at 18:00:00 EEST

The Board of Directors of Revenio Group Corporation has decided, on the basis of the share issue authorization granted to the Board of Directors by the company's Annual General Meeting held on April 4, 2024, to issue shares in a directed share issue without payment to pay the shares from the 2023 earnings period earned by the company's subsidiary Oculo's (nowadays Icare World Australia Pty Ltd.) key persons during the performance period 2021-2023 of the share-based incentive scheme.

The arrangement was established to form part of the long-term incentive and commitment program for certain key employees of Oculo. The arrangement aimed to support the implementation of the company's strategy, combine the interests of the shareholders and the participants in order to increase the value and performance of the company in the long-term, and commit participants to the Company after the acquisition. The maximum number of shares in the program was limited. Under the program, shares were issued for a maximum total value of AUD 1,660,000, calculated at the trading-weighted average price on the closing date April 27, 2021 of the Oculo acquisition. The arrangement was a three-year performance share plan for the calendar years 2021, 2022 and 2023, respectively.

A total of 833 of the company's treasury shares will be transferred in a directed issue free of charge to persons included in the share-based incentive scheme. After the transfers, the company will hold 84,309 treasury shares.

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki Ltd

Financial Supervisory Authority (FIN-FSA)

Main media

www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

REVENIO

In 2023, the Group's net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation to transfer shares related to the Oculo share-based incentive scheme for 2021-2023](#)